Oncoustics’ Post

Exciting news from the Medtech frontier! SonoVascular, Inc. is setting new standards in VTE treatment with their SonoThrombectomy™ system. This innovative approach combines microbubble-mediated cavitation with low-dose thrombolytics, achieving impressive results. At DIPRECA Hospital in Santiago, Chile, the first patient treated was discharged just 48 hours later, showcasing a swift, complication-free recovery. This breakthrough underscores the potential of SonoThrombectomy™ to transform VTE care by preserving vascular integrity while ensuring rapid clot removal. As we continue to explore Medtech innovations, Bioaccess® stands ready to support startups with early feasibility clinical trials across Latin America, providing vital insights and opportunities. Stay ahead with us in this evolving landscape. 🌍💡 #Medtech #ClinicalTrials https://lnkd.in/eEYJahrR

In the realm of VTE treatments, a remarkable transformation is underway. Traditional VTE treatments often involve invasive procedures, risking blood loss and prolonged recovery periods. Enter SonoVascular's SonoThrombectomy™ system, a groundbreaking solution that redefines safety and efficiency. By integrating microbubble-mediated cavitation with controlled thrombolytic delivery, this system has achieved rapid thrombus elimination while preserving vascular integrity. At DIPRECA Hospital in Santiago, Chile, the first patient treated with this method was discharged in just 48 hours, marking a significant milestone in VTE care. This advancement not only accelerates recovery but also enhances patient safety, avoiding the ICU requirement. For Medtech startups aiming to bring such innovations to life, bioaccess® is here to support your early feasibility clinical trials in Latin America. 🌟#VTE #MedtechInnovation https://lnkd.in/eEYJahrR

At DIPRECA Hospital in Santiago, Chile, a patient’s journey to recovery took an extraordinary turn. With a condition as serious as venous thromboembolism (VTE), the stakes were high. Yet, the innovative SonoThrombectomy™ system by SonoVascular, Inc. offered hope. This groundbreaking system, combining microbubble-mediated cavitation with low-dose thrombolytic delivery, treated the patient effectively and safely. In just 48 hours post-procedure, the patient was discharged, marking a swift and smooth recovery without complications. The potential for this system to revolutionize VTE treatment is evident. 🌟 As we celebrate this milestone, it's crucial to acknowledge the support of Medtech CROs like bioaccess®, aiding startups in conducting clinical trials in Latin America. Their involvement is pivotal in advancing such transformative medical innovations. For more insights into our journey, visit our website. #Medtech #VTEtreatment https://lnkd.in/eEYJahrR

Serum β2-Microglobulin Predicts Time to Recovery of Delayed Graft Function in Kidney Transplant Recipients Serum β2-Microglobulin Predicts Time to Recovery of Delayed Graft Function in Kidney Transplant Recipients Background Delayed graft function (DGF) after kidney transplantation can lead to negative patient and allograft outcomes. Prolonged DGF is linked to worse graft outcomes. The relationship between posttransplant serum β2-microglobulin (B2M) and DGF recovery is not well understood. Methods All kidney-only transplant recipients with DGF from the E-DGF trial were included. DGF duration was defined as the time between transplant and the last dialysis session. The association of standardized serum creatinine (Scr) and B2M on postoperative Days 1-7 with DGF recovery was analyzed. Results 97 recipients with DGF were included, with a mean DGF duration of 11.0 ± 11.2 days. Higher Scr was not associated with DGF duration, but higher standardized B2M was linked to a prolonged DGF duration. This association remained even after adjusting for baseline characteristics. Conclusion B2M is more strongly associated with DGF recovery than Scr. Posttransplant B2M may be an important biomarker to monitor during DGF. Trial Registration ClinicalTrials.gov identifier: NCT03864926 Practical Solutions and Value Clinical trials are crucial for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research into an easily accessible knowledge base for clinicians. Streamlining operations is essential in today’s healthcare environment, and our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally. By using AI, clinics can enhance their workflows, improve patient outcomes, and reduce paper routines. https://lnkd.in/g86nvied #ClinicalTrials #AIinHealthcare #MedicalAI #HealthTech #DigitalHealth #PatientCareAI #AIResearch #MedicalInnovation #BioTech #AIforGood #HealthcareData #AIinMedicine #PharmaAI #ClinicalData #HealthAI #AIHealthSolutions #PrecisionMedicine #AIandHealth #ClinicalAnalytics #AIDiagnostics

nference is proud to announce a strategic research alliance with Takeda, aimed at advancing precision medicine in the treatment of Inflammatory Bowel Disease (#IBD). Introducing Project #SUCCINCT (Systematic UC & Crohn’s INformatics Clinical Toolkit), an innovative initiative leveraging our advanced artificial intelligence (#AI) capabilities to analyze de-identified electronic health records. This collaboration seeks to identify personalized treatment approaches, thereby improving patient care for those affected by IBD. IBD, which includes Crohn’s disease and ulcerative colitis, is a chronic and debilitating condition affecting millions globally. The complexity and variability of IBD pose significant challenges in managing and treating the disease. Identifying effective treatments is crucial for improving the quality of life for patients, reducing healthcare costs, and minimizing the long-term complications associated with the disease. Project SUCCINCT aims to address these challenges by providing more targeted and effective therapeutic options through AI-driven insights. "This initiative will leverage our state-of-the-art AI-enabled platform to unlock previously undiscovered insights and information that will help facilitate more precise and targeted interventions with the disease.” - Maulik Nanavaty, President of Ventures at nference and CEO at Anumana. We are excited about the potential of this collaboration to transform the landscape of IBD treatment and look forward to the advancements it will bring. #PrecisionMedicine #RealWorldEvidence #IBD #nference #Takeda Learn more: https://lnkd.in/eWFzPYPc

New Article! A recent MDPI (Multidisciplinary Digital Publishing Institute) article written by our clinical staff Azia Lavrenyuk, PhD, Maren Fragala, PhD, CSCS.D, Pallavi Upadhyay, PhD, CMPP, Andrea (Janie) French, Steve Goldberg, MD, MBA, and Jay Reddy highlights the significant benefits of syndromic, next-day PCR testing for women’s gynecologic health. Among nearly 2 million women, those tested for vaginitis using next-day syndromic PCR tests experienced fewer outpatient visits and reduced healthcare costs over six months compared to those without diagnostic testing. Results: - Fewer medical services: 18 vs. 21 visits on average. - Lower costs: $6,675 vs. $8,742 in healthcare costs on average. At HealthTrackRx, we are proud to advance molecular diagnostics that improve patient care while reducing healthcare burdens. Click on the link below to find out more! https://bit.ly/3BejsEW #HealthcareInnovation #PCRTesting #WomensHealth #MolecularDiagnostics #HealthTrackRx

Exciting to see Acarix advancing cardiac diagnostics! At Rejuve.Bio, we value innovative approaches to healthcare. Our AI-driven research aims to revolutionize longevity interventions, aligning with Acarix's goal of improving patient outcomes. Learn more about Rejuve.Bio and our crowdfund here bit.ly/rjvbcrowdfund https://lnkd.in/gKi8RGC4

Partnering with an independent diagnostic healthcare lab can offer several benefits compared to utilizing a hospital lab. Here are some key advantages: 1. Cost-Effectiveness: Independent labs often have lower overhead costs than hospital labs. This can translate into more competitive pricing for tests, making it more affordable for patients and healthcare providers. 2. Faster Turnaround Times: Independent labs may have streamlined operations and dedicated resources that allow them to process tests more quickly, leading to faster results for patients and providers. 3. Specialization: Many independent labs focus on specific types of testing or specialized services. This expertise can lead to higher quality results and more accurate diagnostics. 4. Flexibility and Customization: Independent labs may offer more flexible testing options and can often accommodate specific requests or unique testing needs that a larger hospital lab might not be able to. 5. Enhanced Customer Service: Independent labs often pride themselves on personalized service and may provide better communication and support to healthcare providers and their patients. 6. Accessibility: Independent labs may offer more convenient locations and extended hours of operation, making it easier for patients to access testing services without the constraints of hospital hours. 7. Focus on Innovation: Independent labs may be more agile and quicker to adopt new technologies and testing methods, leading to advanced diagnostic options and improved patient care. 8. Reduced Congestion: Hospital labs can sometimes be overwhelmed with high patient volumes, leading to delays. Independent labs may have the capacity to handle cases more efficiently, reducing wait times for patients. 9. Direct Patient Engagement: Some independent labs offer direct-to-consumer testing options, allowing patients to order tests and receive results without needing a physician's order, which can empower patients in managing their health. 10. Regulatory Compliance and Quality Assurance: Many independent labs maintain high standards of quality and compliance, often exceeding regulatory requirements, which can ensure reliable and trustworthy results. While both independent and hospital labs have their merits, these benefits can make independent diagnostic healthcare labs a compelling choice for many healthcare providers and patients seeking efficient and cost-effective laboratory services. #healthcare #partnerships #networking #diagnostics #seniorliving #excellence #teamwork #businessgrowth #michigan #administrators #directorofnursing #executivedirector #healthandwellness #skillednursing #memorycare #assistedliving #visitingphysicians

𝐏𝐫𝐨𝐜𝐞𝐝𝐮𝐫𝐞-𝐁𝐚𝐬𝐞𝐝 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬: 𝐏𝐚𝐫𝐚𝐜𝐞𝐧𝐭𝐞𝐬𝐢𝐬, 𝐓𝐡𝐨𝐫𝐚𝐜𝐞𝐧𝐭𝐞𝐬𝐢𝐬 & 𝐌𝐨𝐫𝐞 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐃𝐞𝐦𝐨 𝐑𝐞𝐩𝐨𝐫𝐭, 𝐄𝐱𝐜𝐞𝐥 𝐏𝐢𝐯𝐨𝐭 𝐚𝐧𝐝 𝐓𝐨𝐂: https://lnkd.in/dJYZdTUP The Global #CentesisCatheters Market Size is valued at 555.08 million in 2023 and is predicted to reach 874.28 million by the year 2031 at a 5.94% CAGR during the forecast period for 2024-2031. ▪ 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐂𝐨𝐯𝐞𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐫𝐞: ▪ AngioDynamics. ▪ Argon Medical Devices, Inc. ▪ Avanos Medical ▪ Axiom Medical. ▪ BD ▪ Blueneem Medical Devices Pvt Ltd ▪ Boston Scientific ▪ Canadian Hospital Specialties Limited ▪ Cardinal Health ▪ Cook Medical ▪ Galt Medical, LLC ▪ KM Medical ▪ Medical Components, Inc. ▪ Medtronic ▪ Merit Medical Systems, Inc. ▪ Mermaid Medical Group ▪ pfm medical, inc. ▪ Redax S.p.A. ▪ Rocket Medical ▪ Teleflex ▪ UreSil, LLC #MedicalDevices #DiagnosticCare #TherapeuticCare #PalliativeCare #HealthcareMarket #MedicalTrends #Paracentesis #Thoracentesis

Diaceutics PLC have announced an open invitation to all stakeholders in precision medicine to join a collaboration to address the economic barriers preventing patient access to life-changing precision medicines at an online event on 1st of May. The 'Precision Medicine Practice Gaps Economic, Policy and Operational Solutions Forum' was established in 2023 to progress research undertaken by Diaceutics and The Personalized Medicine Coalition (PMC) which highlighted that 64.4% of a NSCLC patients in the US may not receive the best treatment for their disease. The forum was established to urgently address the specific economic gaps limiting the advancement of precision medicine and to enable every patient to get the treatment they deserve.  Co-chaired by Susanne Munksted, Chief Precision Medicine Officer at Diaceutics, and Denny Van Liew, Board Member Emeritus at the PMC and veteran Solution Architect and Life Sciences Senior Advisor at Red Nucleus, the forum is composed of leading experts in precision medicine. The solutions and recommendations proposed will be shared for discussion at a virtual global summit this May 1st.  Find out more and register at https://lnkd.in/e5-uyjZv